Help

Breast Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head & Neck Cancer, Lung Cancer, Urothelial Cancer

The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA® (pembrolizumab)

The Agilent Precision Pathology Insights webinar series brings leading pathology experts directly to your computer to discuss topics in the evolving world of PD-L1 staining. This webinar is presented by Dr. Kristopher Kersch, Pathologist at Agilent Technologies. Recorded on 24 September 2019.

Key topics covered by Dr. Kersch are:

Strengths of and differences between Combined Positive Score (CPS)/Tumor Proportion Score (TPS) scoring systems
Clinical trial considerations and the development of CPS/TPS scoring systems
Real-world case examples and calculations

Kristopher Kersch, MD

Pathologist, Agilent Technologies

Related Training

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.D0113749_1.00

The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA® (pembrolizumab)

The Agilent Precision Pathology Insights webinar series brings leading pathology experts directly to your computer to discuss topics in the evolving world of PD-L1 staining. This webinar is presented by Dr. Kristopher Kersch, Pathologist at Agilent Technologies. Recorded on 24 September 2019.​

Kristopher Kersch, MD

Related Training

The Agilent Precision Pathology Insights webinar series brings leading pathology experts directly to your computer to discuss topics in the evolving world of PD-L1 staining. This webinar is presented by Dr. Kristopher Kersch, Pathologist at Agilent Technologies. Recorded on 24 September 2019.